Glioblastoma Multiforme Treatment Market Analysis By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Other Treatments), By Drug Class (Temozolomide, Lomustine, Bevacizumab, Other Drug Classes), By End-use (Hospitals, Clinics, Ambulatory Surgical Centers), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: Oct 2024
- Report ID: 49807
- Number of Pages: 372
- Format:
-
keyboard_arrow_up
-
-
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd. Company Profile
- Merck & Co.Inc.
- Amneal Pharmaceuticals
- Arbor Pharmaceuticals LLC
- Pfizer Inc Company Profile
- Amgen Inc.
- Boston Biomedical Inc.
- Sun Pharmaceutical Industries Ltd.
- Karyopharm Therapeutics Inc.
- Other Key Players
- settingsSettings
Our Clients
- 49807
- Oct 2024
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
